Drug Profile
MK 4965
Alternative Names: MK-4965Latest Information Update: 08 Aug 2011
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Chlorobenzenes; Nitriles; Small molecules
- Mechanism of Action Non-nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported HIV-1 infections
Most Recent Events
- 08 Aug 2011 No development reported - Phase-I for HIV-1 infections in USA (PO)
- 10 Apr 2008 Phase-I clinical trials in HIV-1 infections in USA (PO)
- 05 Sep 2007 Preclinical trials in HIV infections in USA (unspecified route)